Quazepam, A New Benzodiazepine Hypnotic: Intermediate‐Term Sleep Laboratory Evaluation

  title={Quazepam, A New Benzodiazepine Hypnotic: Intermediate‐Term Sleep Laboratory Evaluation},
  author={Anthony Kales and Martin B. Scharf and Constantin R. Soldatos and Edward O. Bixler and Susan B Bianchi and Paula K. Schweitzer},
  journal={The Journal of Clinical Pharmacology},
When quazepam was compared with fiurazepam in animal studies assessing sedation and ataxia, quazepam appeared to be somewhat more potent than fiurazepam, but caused less ataxia.1 Data regarding long-term safety or tolerance of the drug are not yet available, but rising single-dose tolerance studies suggest that quazepam is well tolerated and that its pharmacological effects are similar to those of other benzodiazepines.’ The primary objective of the current study was to evaluate, in the sleep… 
Quazepam: Hypnotic Efficacy and Side Effects
  • A. Kales
  • Medicine, Psychology
  • 1990
Quazepam is a benzodiazepine hypnotic that can be useful in the adjunctive pharmacologic treatment of insomnia and is more effective with short‐term use, and with continued use it maintains its efficacy in contrast to both of these drugs which show rapid development of tolerance.
Comparison of short and long half‐life benzodiazepine hypnotics: Triazolam and quazepam
The 0.25 mg dose of triazolam, which is being prescribed increasingly, has a profile of side effects that is similar to that of the 0.5 mg dose, and is associated with sleep and mood disturbances whereas quazepam exerted carryover effectiveness.
Quazepam and temazepam: Effects of short‐ and intermediate‐term use and withdrawal
Although temazepam was effective for maintaining sleep with short‐term use, there was rapid development of tolerance for this effect with intermediate‐ term use, and quazEPam had carryover effectiveness.
Quazepam and flurazepam: Long‐term use and extended withdrawal
The data suggest that the optimal dose of quazepam is 15 mg, and some loss of effectiveness was noted during long‐term use of both doses of quzepam and, to a lesser extent, of flurazepams.
Dose‐response studies of quazepam
The efficacy and comparatively less severe side effects of the 7.5‐and 15‐mg doses of quazepam suggest that these doses may be optimal when the drug is considered for the adjunctive treatment of insomnia.
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
  • N. Moniri
  • Psychology, Biology
    International clinical psychopharmacology
  • 2019
The purpose of this review is to provide an update on distinguishing features of quazepam with regard to its pharmacology, pharmacokinetics, sleep efficacy and potential adverse effects compared to other agents used for insomnia.
Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance
Performance scores were already showing recovery from peak impairment 2 h post-drug ingestion, although quazepam's potent N-desalkylflurazepAM metabolite has been found to maintain a maximum plateau level from 2 to 24 h.
Effects of quazepam as a preoperative night hypnotic: comparison with brotizolam
The preoperative night hypnotics, quazepam and brotizolam improved sleep before surgery; the frequency of nocturnal awakening and dreaming decreased, and the total duration of sleep the night before surgery increased.
A Comparative 25‐Night Sleep Laboratory Study on the Effects of Quazepam and Triazolam on Chronic Insomniacs
With quazepam, rebound insomnia was not observed at any time during the seven‐day withdrawal period, and both drugs increased the total sleep time during their administration and improved the subjective quality of sleep.


Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines.
Rebound insomnia occurred following withdrawal of triazolam, nitrazepam, and flunitsepam after they had been given in only single, nightly doses for short periods, attributed to the short and intermediate half-lives of these drugs.
Flunitrazepam, an Investigational Hypnotic Drug: Sleep Laboratory Evaluations
It is an analogue of nitrazepam (Mogadon*+), a hypnotic drug which has been widely used in Europe since 1965 but not available for clinical use in the United States. In a preliminary study of the
Effectiveness of hypnotic drugs with prolonged use: Flurazepam and pentobarbital
Pentobarbital was found to be effective in inducing and maintaining sleep only with short‐term drug administration, which strongly suggests that it is of limited value for insomniac patients who require nightly medication beyond short-term use.
Rebound insomnia: a new clinical syndrome.
Rebound insomnia followed the withdrawal of three benzodiazepine hypnotic drugs, each of which had been administered in a single nightly dose for only short-term periods. The intense worsening of
Hypnotic Efficacy of Triazolam: Sleep Laboratory Evaluation of Intermediate‐Term Effectiveness
The data indicate that triazolam is effective for short-term use, loses most of its effectiveness with intermediate- term use, and its withdrawal is followed by a significant sorsening of sleep.
The Effect of a New Benzodiazepine on the Polygraphically Monitored Sleep of Normal Volunteers
The subjective quality of sleep was improved by the new benzodiazepine hypnotic, and one subject reported that he felt lethargic the day after the largest dose.
Nitrazepam: lastingly effective but trouble on withdrawal.
Slow-wave sleep was reduced by nitrazepam, but the accompanying secretion of growth hormone was not impaired, and sleep was longer and less broken on the drug and no tolerance was obvious after two months' use.
Effectiveness of Temazepam with Short‐, Intermediate‐, and Long‐Term Use: Sleep Laboratory Evaluation
Effectiveness of 30 mg temazepam for inducing and maintaining sleep was evaluated in the sleep laboratory in six insomniac subjects under conditions of short-, intermediate-, and long-term drug administration, and effectiveness was not demonstrated for sleep maintenance.
Sleep laboratory studies of flurazepam: A model for evaluating hypnotic drugs
The results from six separate evaluations of flurazepam 30 mg in the sleep laboratory were combined to determine the effectiveness of the drug in inducing and maintaining sleep and its effects on
Effects of placebo and flurazepam on sleep patterns in insomniac subjeets
There was agreement between the subjectioe estimates of sleep and the electroencephalogram (EEG) data in terms of both improvement in sleep induction and sleep maintenance with flurazepam and in the lack of effects with placebo.